These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23281842)

  • 1. Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5.
    Gravesen E; Hofman-Bang J; Lewin E; Olgaard K
    Scand J Clin Lab Invest; 2013 Mar; 73(2):107-16. PubMed ID: 23281842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL; Hristova M; Ho LT; Sprague SM
    Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
    Thimachai P; Supasyndh O; Chaiprasert A; Satirapoj B
    J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency.
    Trakarnvanich T; Chalapipat O; Disthabanchong S; Kurathong S; Praditpornsilpa K; Stitchantrakul W; Chailurkit LO
    J Med Assoc Thai; 2010 Aug; 93(8):885-91. PubMed ID: 20718162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
    Blair D; Byham-Gray L; Lewis E; McCaffrey S
    J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
    D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calculated free and bioavailable vitamin D metabolite concentrations in vitamin D-deficient hip fracture patients after supplementation with cholecalciferol and ergocalciferol.
    Glendenning P; Chew GT; Inderjeeth CA; Taranto M; Fraser WD
    Bone; 2013 Oct; 56(2):271-5. PubMed ID: 23792937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.
    Wetmore JB; Kimber C; Mahnken JD; Stubbs JR
    Br J Nutr; 2016 Dec; 116(12):2074-2081. PubMed ID: 28065190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
    Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
    Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
    Susantitaphong P; Nakwan S; Peerapornratana S; Tiranathanagul K; Katavetin P; Srisawat N; Praditpornsilpa K; Eiam-Ong S
    BMC Nephrol; 2017 Jan; 18(1):19. PubMed ID: 28088187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.
    Al-Aly Z; Qazi RA; González EA; Zeringue A; Martin KJ
    Am J Kidney Dis; 2007 Jul; 50(1):59-68. PubMed ID: 17591525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency.
    Leventis P; Kiely PD
    Scand J Rheumatol; 2009; 38(2):149-53. PubMed ID: 18991184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of fibroblast growth factor-23 in chronic kidney disease.
    Westerberg PA; Linde T; Wikström B; Ljunggren O; Stridsberg M; Larsson TE
    Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
    Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.
    Saji F; Shigematsu T; Sakaguchi T; Ohya M; Orita H; Maeda Y; Ooura M; Mima T; Negi S
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1212-7. PubMed ID: 20739393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
    Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.